Rapport Therapeutics, Inc. (RAPP) income statement
RAPPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$23.40−0.36 (-1.52%)
Close on Nov 18, 2026Market cap $1.12BP/E –Yield –
Rapport Therapeutics, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -28.2%
Financial strength
- Current ratio
- 20.07
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 368.2%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.87
- Dividend yield
- –
See a number that looks wrong?